Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Int J Mol Sci. 2020 May 16;21(10):3532. doi: 10.3390/ijms21103532.
Very few data are reported in the literature on the association between elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) and prognosis in advanced colorectal cancer. Moreover, there is no information available in relation to the response to antiangiogenic treatment. We analyzed EMAST and vascular endothelial growth factor-B (VEGF-B) microsatellite status, together with standard microsatellite instability (MSI), in relation to prognosis in 141 patients with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT) alone ( = 51) or chemotherapy with bevacizumab (B) (CT + B; = 90). High MSI (MSI-H) was detected in 3% of patients and was associated with progression-free survival (PFS; = 0.005) and overall survival (OS; < 0.0001). A total of 8% of cases showed EMAST instability, which was associated with worse PFS ( = 0.0006) and OS ( < 0.0001) in patients treated with CT + B. A total of 24.2% of patients showed VEGF-B instability associated with poorer outcome in ( = 0.005) in the CT arm. In conclusion, our analysis indicated that EMAST instability is associated with worse prognosis, particularly evident in patients receiving CT + B.
在高级结直肠癌中，微卫星高度改变（EMAST）与预后之间的相关性的相关文献中仅报道了很少的数据。此外，关于抗血管生成治疗的反应，尚无相关信息。我们分析了在接受单独化疗（CT；=51）或化疗联合贝伐单抗（CT+B；=90）治疗的 141 例转移性结直肠癌（mCRC）患者中，EMAST 和血管内皮生长因子-B（VEGF-B）微卫星状态与预后之间的关系，以及标准微卫星不稳定性（MSI）。3%的患者检测到高 MSI（MSI-H），并与无进展生存期（PFS；=0.005）和总生存期（OS；<0.0001）相关。共有 8%的病例显示 EMAST 不稳定，这与接受 CT+B 治疗的患者的更差 PFS（=0.0006）和 OS（<0.0001）相关。共有 24.2%的患者显示 VEGF-B 不稳定，与 CT 组的较差预后相关（=0.005）。总之，我们的分析表明，EMAST 不稳定与预后较差相关，在接受 CT+B 治疗的患者中更为明显。
